Skip to Content
 

VICC toll-free number 1-877-936-8422

Hematologic Cancers

The Hematology Clinic is located on the second floor of The Vanderbilt Clinic and is open from Monday through Friday from 8:00 a.m. to 5:00 p.m. Our physicians see patients with hematologic malignancies, benign hematologic disorders and specialty clinics for sickle cell anemia and hemostasis and thrombosis.

Clinical Trials for Hematologic Cancers

42 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Leukemia

VICCHEM1305

04/02/2013

Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Basic Science

Leukemia

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

Hematologic

VICCBMT1008

02/18/2010

Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity (deidentified)

Basic Science

Hematologic

NMDPBMT0346

07/09/2003

Repository for National Donor Program (NMDP) Research Blood Samples.

Diagnostic

Leukemia

ECOGHEMEAI141

05/10/2016

Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

Other

Hematologic
Leukemia
Myelodysplastic Syndrome
Pediatric Leukemia

VICCPED1639

09/28/2016

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Other

Leukemia

VICCHEM14133

11/11/2015

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Other

Myelodysplastic Syndrome

VICCBMT1407

04/17/2015

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Other

Multiple Myeloma

VICCHEM1470

11/05/2014

Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

Other

Hematologic

VICCBMT1401

08/29/2014

Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

Other

Hematologic

VICCBMT1110

11/02/2001

Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

Supportive Care

Hematologic

VICCBMT1426

11/10/2014

Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

Supportive Care

Leukemia
Pediatric Leukemia

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Treatment

Leukemia
Myelodysplastic Syndrome

VICCHEM1660

09/27/2016

A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Treatment

Leukemia
Multiple Myeloma

VICCHEM1621

09/16/2016

An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

Treatment

Leukemia

VICCHEM1654

09/09/2016

An Open-Label, Multi-Center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-Like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who are Eligible for Standard Induction and Consolidation Chemotherapy

Treatment

Lymphoma

ECOGHEME4412

08/18/2016

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Treatment

Hematologic

VICCHEM1613

08/02/2016

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

Treatment

Hematologic
Leukemia
Lung
Miscellaneous
Small Cell

VICCHEMP1615

07/21/2016

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

Treatment

Lymphoma
Miscellaneous

VICCPHI1616

06/08/2016

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Treatment

Leukemia

VICCHEM15113

05/06/2016

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

Treatment

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

VICCPED1537

04/28/2016

T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Treatment

Leukemia
Pediatric Leukemia

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

Multiple Myeloma

VICCBMT1566

04/21/2016

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

Treatment

Hematologic

VICCHEM1580

03/11/2016

A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post - Polycythemia Vera MF (post-PV MF), or Post -Essential Thrombocythemia MF (post-ET MF)

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Leukemia

VICCHEM1597

02/17/2016

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Treatment

Leukemia
Pediatric Leukemia

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

Multiple Myeloma

VICCHEM15112

01/11/2016

A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

Treatment

Hematologic

VICCHEM1565

01/05/2016

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

Treatment

Multiple Myeloma

VICCHEM14131

11/17/2015

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

Treatment

Lymphoma

VICCHEM14125

11/13/2015

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Treatment

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

Multiple Myeloma

VICCHEM1437

09/29/2015

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

Treatment

Multiple Myeloma

VICCHEM1526

07/01/2015

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-Refractory to Previous Therapies

Treatment

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

Leukemia

VICCHEM1505

05/06/2015

An Open-Label Phase I Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1143572 given in a Once-Daily or an Intermittent Dosing Schedule in Subjects with Advanced Acute Leukemia

Treatment

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Treatment

Leukemia

VICCHEM1294

02/25/2013

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Treatment

Lymphoma

VICCHEM1146

08/14/2012

Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

Treatment

Hematologic

VICCBMT1158

10/20/2011

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications